Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378961 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT02378961 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 128 participants.
The verdict
NCT02378961, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.
Interventions
- DRUG SOF/VEL
- DRUG VOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-02-16 |
| Est. Completion | 2016-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02378961
The ClinicalTrials.gov registry entry for NCT02378961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SOF/VEL is the first listed.
NCT02378961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02378961 about?
NCT02378961 is a clinical study titled "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection". The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in adults with chronic non genotype 1 hepatitis C virus (HCV) infection.
What is the current status of trial NCT02378961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2015-02-16. Estimated completion is 2016-01-26.
What interventions are being tested in trial NCT02378961?
The interventions under investigation include: SOF/VEL (DRUG), VOX (DRUG).
Who is sponsoring clinical trial NCT02378961?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.